Medical researchers have unveiled promising results for a new approach to treating brain cancer that could transform patient outcomes following surgery.
Scientists presented findings at a major oncology conference showing that a small radiation-emitting device implanted during brain tumor removal surgery delivers superior results compared to conventional radiation therapy.
The innovative treatment involves placing a thin collagen tile infused with cesium-131 radiation directly into the space where surgeons removed the tumor. This device immediately begins destroying any remaining cancer cells while traditional treatments require patients to wait up to six weeks after surgery before radiation can begin.
During this waiting period with standard care, leftover cancer cells in the brain can multiply and spread, researchers explained. The new implant eliminates this dangerous gap by providing instant radiation treatment that gradually diminishes as the device dissolves naturally into the body.
A comprehensive study involving 230 patients with operable brain metastases compared outcomes between those receiving the implant versus standard radiation therapy after surgery.
The results showed dramatic improvements: only 1% of patients with the implant experienced tumor regrowth in the surgical site after one year, compared to 11.9% of those receiving conventional treatment.
Patients who received the device had more than a 50% lower risk of cancer returning or dying compared to standard care. Two-year survival rates reached 61.7% with the implant versus 35.7% for traditional radiation.
Side effects and quality of life measures remained comparable between both treatment approaches, according to researchers.
“These patients have faced important challenges with existing treatment approaches,” stated the chief medical officer of the company that developed the technology.
He added that the study data “delivers the high level of evidence to support GammaTile as a new up-front treatment option.”
In related cancer treatment advances, researchers also reported breakthrough results for patients with relapsed multiple myeloma using a new dual-action drug that helps the immune system recognize and attack cancer cells directly.
Additionally, an experimental vaccine combined with immunotherapy reduced melanoma recurrence by nearly half in a five-year study, offering hope for personalized cancer treatments that target specific tumor characteristics.
